

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6958557

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	KANION USA INC.	09/27/2012
RECEIVING PARTY DATA		
Name:	NEWGEN THERAPEUTICS, INC.	
Street Address:	3475 EDISON WAY, SUITE R	
City:	MENLO PARK	
State/Country:	CALIFORNIA	
Postal Code:	94025	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16666307
CORRESPONDENCE DATA		
Fax Number:	(650)494-0792	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4152686431	
Email:	mleung@mofo.com	
Correspondent Name:	STEPHANIE CHOING	
Address Line 1:	MORRISON & FOERSTER LLP	
Address Line 2:	425 MARKET STREET	
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105	
ATTORNEY DOCKET NUMBER:	22738-20001.03	
NAME OF SUBMITTER:	STEPHANIE CHOING	
SIGNATURE:	/Stephanie Choing/	
DATE SIGNED:	10/07/2021	
Total Attachments: 2		
source=22738-2000103_Kanion_to_NewGen#page1.tif		
source=22738-2000103_Kanion_to_NewGen#page2.tif		

ASSIGNMENT

This Assignment is by:

1. Kanion USA Inc.
3916 Trust Way
Hayward, California 94545

(referred to in this Assignment as "Assignor"), who resides or has a mailing address as listed above.

This Assignment is to:

1. NewGen Therapeutics, Inc.
3475 Edison Way, Suite R
Menlo Park, CA 94025
A corporation duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), who desires to acquire Assignor's entire right, title and interest in said inventions and said application for letters patent of the United States, and in any United States or foreign, letters patent or patents, to be obtained therefor and thereon.

Assignor has acquired by assignment, certain right, title and interest in certain new and useful inventions in:

TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE

For which the following PCT application has been filed:

Serial No.: PCT/US2012/040304

Filing Date: May 31, 2012

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, Patent Cooperation Treaty (PCT) application and any application for letters patent claiming priority thereto, and any and all letters patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all provisionals, national stage applications, divisions, continuations, continuations-in-part and substitutions of said application, or reissues, re-examinations or extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor represents, warrants and covenants that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement.
3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee of letters patent for said inventions, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) letters patent for said inventions in any country, including any reissue, re-

examination or extension of or interference proceedings; or (c) any provisional, division, continuation, continuation-in-part, or substitutions of any application for letters patent or any reissues, re-examinations, extensions or interference proceedings involving any letters patent, to be obtained thereon. To be clear, for purposes of this paragraph, "desirable" shall include, without limitation, any act necessary or useful in connection with United States laws and/or international conventions.

4. Assignor hereby authorizes and requests National Patent Offices to issue the above mentioned letters patents granted for National and Regional Phase Patent Applications derived from said PCT Application to said Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. "I hereby grant Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known."

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

Assignor:

Date: 9/27/2012

Signature: _____

Wang Shen, President
Kanion USA Inc.

Assignee:

Date: 9/27/2012

Signature: _____

Harry D. Pedersen, President and CEO
NewGen Therapeutics, Inc.